Vanda Pharmaceuticals Reports Revenue Decline and Increased Net Loss in Q2 2026

Vanda Pharmaceuticals Inc. reported a decrease in total revenues for the second quarter of 2026, with net product sales falling to $50.5 million, down 4% from $52.6 million in the same period last year. The decline was primarily driven by a significant drop in sales of HETLIOZ®, which decreased by 66% to $5.6 million, attributed to ongoing generic competition and elevated inventory levels at specialty pharmacy customers. In contrast, sales of Fanapt® increased by 23% to $36.0 million, reflecting strong demand, while PONVORY® sales rose by 12% to $7.9 million. Newly launched NEREUSTM generated $1.0 million in sales during its initial quarter of availability.

For the first half of 2026, Vanda's total revenues were $102.2 million, a slight decrease from $102.6 million in the prior year. Fanapt® sales increased by 24% to $65.5 million, while HETLIOZ® sales fell by 42% to $21.5 million. PONVORY® also saw an 11% increase in sales to $14.1 million, and NEREUSTM contributed $1.0 million in its first two months of sales. The company reported a net loss of $62.5 million for the second quarter, compared to a loss of $27.2 million in the same quarter of 2025, and a total net loss of $111.1 million for the first half of 2026, up from $56.7 million in the prior year.

Vanda's operating expenses increased significantly, with research and development costs rising by 68% to $37.0 million in the second quarter, driven by investments in ongoing clinical trials and product development. Selling, general, and administrative expenses also increased by 11% to $71.8 million, reflecting the costs associated with the commercialization of NEREUSTM and the expansion of the sales force. The company’s total cash and cash equivalents, along with marketable securities, decreased to $170.0 million as of June 30, 2026, down from $263.8 million at the end of 2025.

Strategically, Vanda is focused on expanding its product portfolio and market presence. The FDA approved BYSANTITM for bipolar I disorder and schizophrenia in early 2026, with plans for its launch in the second half of the year. The company also initiated the commercial launch of NEREUSTM in May 2026, which is expected to enhance its market position. Vanda is actively pursuing regulatory approvals for additional indications and products, including QuimilzaTM, which is under review by the FDA.

Looking ahead, Vanda anticipates continued fluctuations in its financial performance due to various factors, including the success of its product launches, ongoing regulatory developments, and the competitive landscape. The company believes its current cash reserves will be sufficient to support operations for at least the next 12 months, although it may seek additional capital to finance future growth initiatives.